(1) Parkinson's disease: An overview

Pharmaceutical Journal

Volumn 264, Issue 7085, 2000, Pages 333-337

  Burn, David ^b  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMPHOTERICIN B; CALCIUM CHANNEL BLOCKING AGENT; DOXORUBICIN; FLUOROURACIL; LITHIUM; NEUROLEPTIC AGENT; PETHIDINE; PHENELZINE; TETRABENAZINE; VINCRISTINE;

CLINICAL FEATURE; DEPRESSION; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; INCIDENCE; LEWY BODY; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; REVIEW; SOCIOECONOMICS;

EID: 0034716617     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely & Jones, 1817.
2. Ben-Shlomo Y. The epidemiology of Parkinson's disease. In: Quinn NP, editor. Parkinsonism. London: Ballière Tindall, 1997:55.
3. Zhang Z-X, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993;12:195.
4. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 1985;35:841.
5. Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, et al. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in Northern Manhattan, 1988-1993. Am J Epidemiol 1995;142:820.
6. Polymeropoulos MH, Higgins JJ, Golbe LI, Nussbaum RL. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996;274:1197.
7. Vaughan JR, Farrer MJ, Wszolek ZK, Gasser T, Durr A, Agid Y, et al. Sequencing of the α synuclein gene in a large series of cases of familial Parkinson's disease fails to reveal any further mutations. Hum Mol Genet 1998;7:751.
8. Abbas N, Lucking CB, Richard S, et al. A wide variety of mutations in the parkin gene is responsible for autosomal recessive parkinsonism in Europe. Hum Mol Genet 1999;8:567.
9. Gasser T, Muller-Myhsok B, Wzolek K, Oehlman R, Calne DD, Bonifati V, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nature Genet 1998;18:1.
10. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017.
11. Bordet R, Broly F, Destee A, Libersa C. Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson's disease and diffuse Lewy body disease. Clin Neuropharmacol 1994;17:484.
12. Gasser T, Muller-Myhsok B, Supala A, Zimmer E, Wieditz G, Wszolek ZK, et al. The CYP2D6B allele is not over represented in a population of German patients with idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:518.
13. Plante-Bordeneuve V, Taussig D, Trassard O, Said G, Wood NW, Marsden CD, et al. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease. Neurology 1997;48:1589.
14. Kurth J, Kurth M, Podulso S, Schwankhaus J. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993;33:368.
15. Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW. Association of slow acetylator genotype for N-acetyl transferase 2 with familial Parkinson's disease. Lancet 1997;350:1136.
16. Nicholl DJ, Bennett P, Hiller L, Bonifati V, Vanacore N, Fabbrini G, et al. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. Neurology 1999;53:1415.
17. Gibb WR. Neuropathology of Parkinson's disease and related syndromes. Neurologic Clinics 1992;10:361.
18. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585.
19. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Ibid1991;114:2283.
20. Menza M, Forman NE, Goldstein HE, Golbe LI. Parkinson's disease, personality and dopamine. J Neuropsychiatry Clin Neurosci 1990;2:282.
21. Quinn NP. Parkinson's disease: clinical features. In: Quinn NP, editor. Parkinsonism. London: Ballière Tindall, 1997:1.
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181.
23. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci 1991;18:275.
24. Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, editor. Movement Disorders 3. Oxford: Butterworth-Heinemann; 1994:262.
25. Litvan I. Progressive supranuclear palsy and corticobasal degeneration. In: Quinn NP, editor. Parkinsonism. London: Ballière Tindall; 1997:167.
26. Anton-Stephens D. Preliminary observations on the psychiatric uses of chlorpromazine (Largactil). J Mental Sci 1954;100:543.
27. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054.
28. Chabolla DR, Maraganore DM, Ahlskog JE, O'Brien PC, Rocca WA. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota. Mayo Clin Proc 1998;73:724.
29. Hallett M, Litvan I, and the Task Force on Surgery for Parkinson's Disease. Evaluation of surgery for Parkinson's disease. Neurology. 1999;53:1910.
30. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson's disease: a baseline analysis of the DATATOP cohort. Neurology 1990;40:1529.
31. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49:381.
32. Findley L, on behalf of the Global Parkinson's Disease Steering Committee. Investigating factors which may influence quality of life in Parkinson's disease. Parkinsonism Rel Disord 1999;5 (suppl):S55.
33. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41:202.
34. Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992;49:492.
35. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113.
36. The Parkinson's Disease Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757.
37. Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease: a retrospective comparison. Acta Neurol Scand 1995;91:98.
38. Ebmeier KP, Calder SA, Crawford JR, Stewart L, Besson JA, Mutch WJ. Parkinson's disease in Aberdeen: survival after 3.5 years. Ibid 1990;81:294.
39. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, et al. Prevalence of Parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71.
40. Rajput AH, Pahawa R, Pahawa P, Rajput A. Prognostic significance of the onset mode in parkinsonism. Neurology 1993;43:829.
41. The Parkinson's Disease Society (UK). Meeting a need? Discussion Document. London; 1994:11.
42. Dodel RC, Eggert KM, Oertel WH. Costs of Parkinson's disease: a preliminary retrospective survey. In: Stern MB, ed. Beyond the decade of the brain. Royal Tunbridge Wells: Wells Medical Ltd; 1994:59.